Callister Pharmaceuticals Files for Patent of Nurvana

Callister Pharmaceuticals has officially filed for a patent for a treatment called Nurvana. This pharmaceutical treatment is still under development, but pre-clinical data have shown that it can reduce the effects of ischemic stroke.

Cardiovascular disease is a top health ailment and cause of death in the United States. One in six deaths due to cardiovascular disease are due to stroke, according to the Centers for Disease Control and Prevention. Statistics also show that every 40 seconds, someone in the United States has a stroke, and a majority of 87% of strokes are ischemic.

In the case of an ischemic stroke, a blood clot becomes lodged within a blood vessel in the brain. The blood clot prevents blood from flowing into the brain, which essentially starves the organ of oxygen. It has been traditionally noted that the longer a blood clot remains inside a blood vessel in the brain, the worse the stroke symptoms will be for the long-term. Within minutes of a stroke, cells begin to die, which causes symptoms such as sudden numbness and weakness of the face, arm, or leg; confusion; impaired vision; difficulty with walking and balance; severe headache; and more.

Stroke is the leading cause of long-term disability in the United States. A patient’s lack of mobility can drastically reduce their quality of life. Current treatments are targeted at reducing the effects of the stroke at its onset, as well as long-term therapy.

Ischemic stroke can’t always be caught early enough for treatments to be effective. For instance, once someone realizes they are having a medical emergency, it can take quite some time for them to get help. As the clock ticks, they are experiencing worsening symptoms and neurological damage. Once they do arrive at the emergency room, doctors and healthcare staff typically administer tissue plasminogen activators to break up the blood clot(s) in the brain. This treatment is only effective within four hours of onset of symptoms.

Mechanical thrombectomy is another option for reducing stroke effects. This is an invasive method that involves physically removing the clot using a wire-cage stent retriever. As with chemical destruction of the blood clot, time is of essence; mechanical thrombectomy must be carried out within six hours of onset of symptoms.

For patients who survive ischemic stroke with long-term side effects, there are few effective treatments available. The gold star treatment for long-term treatment has thus far been physical therapy and/or occupational therapy. These treatments are designed to help the patient learn how to do simple things again such as walk, sit, and stand. Unfortunately, this has been the height of long-term stroke care for many years and show little to no benefit after six months.

Callister Pharmaceuticals has filed a patent for Nurvana, a proprietary investigational drug for ischemic stroke recovery. Thus far, pre-clinical insights have shown that Nurvana could help improve motor skills and memory post-ischemic stroke. In addition, Nurvana could also reduce damage in first-time ischemic stroke or in future strokes. Pre-clinical data also indicates that Nurvana could reduce inflammation, scar tissue, and cell death while improving neuronal repair after an ischemic stroke.

Callister Pharmaceuticals outlines the importance of treatments such as Nurvana: “We have been long overdue for a treatment other than physical therapy to help recover from Ischemic Stroke. We want to lead the industry in efforts to solve the number one cause of long-term disability and Nurvana might be the first to do so.”

Stay up to date with the latest developments and future release of Nurvana by visiting https://www.nurvanarx.com/. Details about Callister Pharmaceuticals can be found at https://www.callisterph.com/.

Disclaimer: The statements made regarding these products have not been evaluated by the Food and Drug Administration. This press release is not intended to be a substitute for professional medical advice, diagnosis, or treatment. The news site hosting this press release is not associated with Callister Pharmaceuticals. It is merely publishing a press release announcement submitted by a company, without any stated or implied endorsement of the product or service.

About Callister Pharmaceuticals

Callister Pharmaceuticals offers market research, development, and distribution of groundbreaking FDA-approved treatments.

Press Contact

Name: Bruce Huici Phone: 786-323-6936 Email: Contact Us Website: http://www.callisterph.com/